Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in  Newly Diagnosed Acute Myeloid Leukemia

ConclusionsNewly diagnosed AML patients withAML1/ETO fusion had a poor response to frontline VEN/HMA treatment. When determining induction therapy for patients withAML1/ETO-positive AML, IC should be preferred over VEN/HM.

Source: Targeted Oncology - March 11, 2024 Category: Cancer & Oncology Source Type: research